By Fineline Cube 
China-based Lifetech Scientific Corporation (HKG: 1302) announced plans to invest RMB 150 million (USD 21 million) in AffectOR MedTech, a compatriot firm specializing in electrophysiology and innovative medical devices. The investment will be made in installments, with 22.22% of AffectOR’s equity obtained immediately upon the first phase’s completion. The remaining investment will be contingent on milestone achievements, including AffectOR securing marketing approvals from China’s National Medical Products Administration (NMPA) for specific products.
Strategic Collaboration and Benefits
Upon transaction completion, Lifetech will gain the right to nominate directors to AffectOR’s board and engage in strategic collaborations in R&D and market expansion. The focus will be on developing, selling, and commercializing innovative cardiac interventional imaging platforms. Additionally, Lifetech will secure exclusive priority cooperation rights and overseas exclusive distribution rights for AffectOR’s electrophysiology products.
AffectOR’s Background and Achievements
Founded in 2021, AffectOR has established itself as a high-tech company in the electrophysiology space. Recently, the company received NMPA approval for its in-house developed StarTrek 3D Mapping System, highlighting its commitment to advancing medical device innovation.-Fineline Info & Tech